Kindly refer to attachment

Profit growth above 25%EBITDA margin expansionExceptional itemResults View source PDF Explain this filing

INDIAGLYCO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-6.4%Reaction day

₹1085.00

prior close

₹1065.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.4%-6.0% vs market

Breweries & Distilleries peers, median of 25sector-1.1%-5.2% vs sector

On the reaction day the stock moved 6.0 pts less than Nifty Microcap 250 and 5.2 pts less than its Breweries & Distilleries peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-3.0

10m

-2.9

15m

-3.4

30m

-2.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-6.4-0.4-6.0-1.1-5.2

Next day

-6.8-1.7-5.1-2.5-4.3

-8.0-1.3-6.7-2.7-5.3

-8.4-0.7-7.7-2.7-5.6

-8.6+0.4-9.0-3.5-5.1

-9.2+0.5-9.7-3.7-5.5

-7.1+2.8-9.9-1.8-5.3

15d

-10.1+1.2-11.3-4.3-5.8

-10.0+5.3-15.4-2.1-7.9

+5.1+9.9-4.8-3.9+8.9

-1.6+13.1-14.7-5.4+3.8

UpDownMarket · Nifty Microcap 250Sector · Breweries & Distilleries peers, median of 25Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

India Glycols reported strong full-year results for FY2026 with standalone revenue of Rs 9,826 crore, up 8.7% from Rs 9,038 crore in the previous year. Standalone profit after tax (PAT) surged 56.5% to Rs 282 crore versus Rs 180 crore, driven by EBITDA growth of 32.4% to Rs 690 crore. The company declared an interim dividend of Rs 7.50 per share. The auditors issued an unmodified (clean) opinion on both standalone and consolidated financials. Key corporate actions include completion of a Rs 467 crore preferential equity allotment and ongoing NCLT approval for demerger of its Bio Pharma and Spirits & Biofuel businesses into separate listed entities. A non-recurring exceptional item of Rs 0.83 crore was recorded due to new labour code implementation.

Likely market impact

The robust PAT growth of 56.5% and EBITDA margin expansion indicate strong operational efficiency, which is positive for shareholders. The clean audit opinion and progressing demerger scheme support confidence in corporate governance.